Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, will present data from the Phase 2 clinical trial in acne vulgaris with its lead product candidate, SB204, at the 2014 Annual Meeting of the Society for Investigative Dermatology (SID)  May 7-10, 2014 at the Albuquerque Convention Center in Albuquerque, New Mexico. 
“The statistically significant results Novan recently reported from the Company's Phase 2 study of SB204 are very encouraging, and I look forward to presenting our efficacy and safety data at this prestigious dermatology conference,” said Dr. Rico.  “The very recent news on attempts at further consolidation in the dermatology industry underscores the need for new drugs. At Novan we're mindful of the shortcomings of currently available therapies and are focused on bringing more effective treatments to market that improve the quality of life for patients.”